{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:48:39Z","timestamp":1790034519628,"version":"4.0.1"},"reference-count":162,"publisher":"Aging and Disease","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2021]]},"DOI":"10.14336\/ad.2021.0214","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T17:42:57Z","timestamp":1633023777000},"page":"1675","source":"Crossref","is-referenced-by-count":34,"title":["The Pathogenesis and Treatment of Cardiovascular Autonomic Dysfunction in Parkinson\u2019s Disease: What We Know and Where to Go"],"prefix":"10.14336","volume":"12","author":[{"given":"Shuzhen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingfang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wucheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2021.0214-1","doi-asserted-by":"crossref","unstructured":"LeWitt PA, Kymes S, Hauser RA (2020). Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls. Aging Dis, 11:679-691.","DOI":"10.14336\/AD.2019.0805"},{"key":"key-10.14336\/AD.2021.0214-2","doi-asserted-by":"crossref","unstructured":"Xu J, Fu X, Pan M, Zhou X, Chen Z, Wang D, et al. (2019). Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson\u2019s Disease Patients. Aging Dis, 10:601-610.","DOI":"10.14336\/AD.2018.0615"},{"key":"key-10.14336\/AD.2021.0214-3","doi-asserted-by":"crossref","unstructured":"Qian E, Huang Y (2019). Subtyping of Parkinson\u2019s Disease - Where Are We Up To? Aging Dis, 10:1130-1139.","DOI":"10.14336\/AD.2019.0112"},{"key":"key-10.14336\/AD.2021.0214-4","doi-asserted-by":"crossref","unstructured":"Ziemssen T, Reichmann H (2010). Cardiovascular autonomic dysfunction in Parkinson\u2019s disease. J Neurol Sci, 289:74-80.","DOI":"10.1016\/j.jns.2009.08.031"},{"key":"key-10.14336\/AD.2021.0214-5","doi-asserted-by":"crossref","unstructured":"Jain S, Goldstein DS (2012). Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis, 46:572-580.","DOI":"10.1016\/j.nbd.2011.10.025"},{"key":"key-10.14336\/AD.2021.0214-6","doi-asserted-by":"crossref","unstructured":"Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM (2011). Prevalence of orthostatic hypotension in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord, 17:724-729.","DOI":"10.1016\/j.parkreldis.2011.04.016"},{"key":"key-10.14336\/AD.2021.0214-7","doi-asserted-by":"crossref","unstructured":"Wenning GK, Scherfler C, Granata R, Bosch S, Verny M, Chaudhuri KR, et al. (1999). Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry, 67:620-623.","DOI":"10.1136\/jnnp.67.5.620"},{"key":"key-10.14336\/AD.2021.0214-8","doi-asserted-by":"crossref","unstructured":"Umehara T, Toyoda C, Oka H (2014). Postprandial hypotension in de novo Parkinson\u2019s disease: a comparison with orthostatic hypotension. Parkinsonism Relat Disord, 20:573-577.","DOI":"10.1016\/j.parkreldis.2014.02.007"},{"key":"key-10.14336\/AD.2021.0214-9","doi-asserted-by":"crossref","unstructured":"Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, et al. (2003). Orthostatic hypotension in de novo Parkinson disease. Arch Neurol, 60:1400-1404.","DOI":"10.1001\/archneur.60.10.1400"},{"key":"key-10.14336\/AD.2021.0214-10","doi-asserted-by":"crossref","unstructured":"Ha AD, Brown CH, York MK, Jankovic J (2011). The prevalence of symptomatic orthostatic hypotension in patients with Parkinson\u2019s disease and atypical parkinsonism. Parkinsonism Relat Disord, 17:625-628.","DOI":"10.1016\/j.parkreldis.2011.05.020"},{"key":"key-10.14336\/AD.2021.0214-11","doi-asserted-by":"crossref","unstructured":"Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. (1997). Prevalence of orthostatic hypotension in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry, 63:584-589.","DOI":"10.1136\/jnnp.63.5.584"},{"key":"key-10.14336\/AD.2021.0214-12","doi-asserted-by":"crossref","unstructured":"Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, et al. (2015). Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord, 30:639-645.","DOI":"10.1002\/mds.26079"},{"key":"key-10.14336\/AD.2021.0214-13","doi-asserted-by":"crossref","unstructured":"Palma JA, Kaufmann H (2020). Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges. Semin Neurol, 40:523-539.","DOI":"10.1055\/s-0040-1713846"},{"key":"key-10.14336\/AD.2021.0214-14","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Goldstein DS (2013). Autonomic dysfunction in Parkinson disease. Handb Clin Neurol, 117:259-278.","DOI":"10.1016\/B978-0-444-53491-0.00021-3"},{"key":"key-10.14336\/AD.2021.0214-15","doi-asserted-by":"crossref","unstructured":"Coon EA (2020). Autonomic Dysfunction in the Synucleinopathies. Semin Neurol, 40:492-501.","DOI":"10.1055\/s-0040-1713844"},{"key":"key-10.14336\/AD.2021.0214-16","doi-asserted-by":"crossref","unstructured":"Ma L, Chan P (2020). Understanding the Physiological Links Between Physical Frailty and Cognitive Decline. Aging Dis, 11:405-418.","DOI":"10.14336\/AD.2019.0521"},{"key":"key-10.14336\/AD.2021.0214-17","doi-asserted-by":"crossref","unstructured":"Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI (2018). Orthostatic Hypotension: JACC State-of-the-Art Review. J Am Coll Cardiol, 72:1294-1309.","DOI":"10.1016\/j.jacc.2018.05.079"},{"key":"key-10.14336\/AD.2021.0214-18","doi-asserted-by":"crossref","unstructured":"Cicero CE, Raciti L, Monastero R, Mostile G, Donzuso G, Sciacca G, et al. (2019). Cardiovascular autonomic function and MCI in Parkinson\u2019s disease. Parkinsonism Relat Disord, 69:55-58.","DOI":"10.1016\/j.parkreldis.2019.10.023"},{"key":"key-10.14336\/AD.2021.0214-19","doi-asserted-by":"crossref","unstructured":"Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D (2000). Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke, 31:2307-2313.","DOI":"10.1161\/01.STR.31.10.2307"},{"key":"key-10.14336\/AD.2021.0214-20","doi-asserted-by":"crossref","unstructured":"Rose KM, Tyroler HA, Nardo CJ, Arnett DK, Light KC, Rosamond W, et al. (2000). Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities study. Am J Hypertens, 13:571-578.","DOI":"10.1016\/S0895-7061(99)00257-5"},{"key":"key-10.14336\/AD.2021.0214-21","doi-asserted-by":"crossref","unstructured":"Masaki KH, Schatz IJ, Burchfiel CM, Sharp DS, Chiu D, Foley D, et al. (1998). Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation, 98:2290-2295.","DOI":"10.1161\/01.CIR.98.21.2290"},{"key":"key-10.14336\/AD.2021.0214-22","doi-asserted-by":"crossref","unstructured":"Luukinen H, Koski K, Laippala P, Kivela SL (1999). Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med, 159:273-280.","DOI":"10.1001\/archinte.159.3.273"},{"key":"key-10.14336\/AD.2021.0214-23","doi-asserted-by":"crossref","unstructured":"Sharabi Y, Imrich R, Holmes C, Pechnik S, Goldstein DS (2008). Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson\u2019s disease with orthostatic hypotension. Mov Disord, 23:1725-1732.","DOI":"10.1002\/mds.22226"},{"key":"key-10.14336\/AD.2021.0214-24","doi-asserted-by":"crossref","unstructured":"Albert RH (2016). Response to a Patient\u2019s Failed Swallowing Study: Decisions Regarding Feeding Tubes and Dysphagia. JAMA Intern Med, 176:1431-1432.","DOI":"10.1001\/jamainternmed.2016.4759"},{"key":"key-10.14336\/AD.2021.0214-25","doi-asserted-by":"crossref","unstructured":"Claus I, Muhle P, Czechowski J, Ahring S, Labeit B, Suntrup-Krueger S, et al. (2021). Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson\u2019s Disease. Mov Disord.","DOI":"10.1002\/mds.28552"},{"key":"key-10.14336\/AD.2021.0214-26","doi-asserted-by":"crossref","unstructured":"Yang T, Zhan Z, Zhang L, Zhu J, Liu Y, Zhang L, et al. (2020). Prevalence and Risk Factors for Malnutrition in Patients With Parkinson\u2019s Disease. Front Neurol, 11:533731.","DOI":"10.3389\/fneur.2020.533731"},{"key":"key-10.14336\/AD.2021.0214-27","doi-asserted-by":"crossref","unstructured":"Wang G, Wan Y, Cheng Q, Xiao Q, Wang Y, Zhang J, et al. (2010). Malnutrition and associated factors in Chinese patients with Parkinson\u2019s disease: Results from a pilot investigation. Parkinsonism Relat Disord, 16:119-123.","DOI":"10.1016\/j.parkreldis.2009.08.009"},{"key":"key-10.14336\/AD.2021.0214-28","doi-asserted-by":"crossref","unstructured":"Fereshtehnejad SM, Ghazi L, Sadeghi M, Khaefpanah D, Shahidi GA, Delbari A, et al. (2014). Prevalence of malnutrition in patients with Parkinson\u2019s disease: a comparative study with healthy controls using Mini Nutritional Assessment (MNA) questionnaire. J Parkinsons Dis, 4:473-481.","DOI":"10.3233\/JPD-130323"},{"key":"key-10.14336\/AD.2021.0214-29","doi-asserted-by":"crossref","unstructured":"Soloveva A, Fedorova D, Villevalde S, Zvartau N, Mareev Y, Sitnikova M, et al. (2020). Addressing Orthostatic Hypotension in Heart Failure: Pathophysiology, Clinical Implications and Perspectives. J Cardiovasc Transl Res, 13:549-569.","DOI":"10.1007\/s12265-020-10044-1"},{"key":"key-10.14336\/AD.2021.0214-30","doi-asserted-by":"crossref","unstructured":"Zesiewicz TA, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet HL, et al. (2004). Heart failure in Parkinson\u2019s disease: analysis of the United States medicare current beneficiary survey. Parkinsonism Relat Disord, 10:417-420.","DOI":"10.1016\/j.parkreldis.2004.04.001"},{"key":"key-10.14336\/AD.2021.0214-31","doi-asserted-by":"crossref","unstructured":"Pechstein AE, Gollie JM, Guccione AA (2020). Fatigability and Cardiorespiratory Impairments in Parkinson\u2019s Disease: Potential Non-Motor Barriers to Activity Performance. J Funct Morphol Kinesiol, 5.","DOI":"10.3390\/jfmk5040078"},{"key":"key-10.14336\/AD.2021.0214-32","doi-asserted-by":"crossref","unstructured":"Okada Y, Ito Y, Aida J, Yasuhara M, Ohkawa S, Hirokawa K (2004). Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int, 54:682-687.","DOI":"10.1111\/j.1440-1827.2004.01680.x"},{"key":"key-10.14336\/AD.2021.0214-33","doi-asserted-by":"crossref","unstructured":"Latt MD, Lewis S, Zekry O, Fung VSC (2019). Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson\u2019s Disease. Drugs Aging, 36:189-202.","DOI":"10.1007\/s40266-018-0629-0"},{"key":"key-10.14336\/AD.2021.0214-34","doi-asserted-by":"crossref","unstructured":"Kondo M, Ueda Y, Makino M, Nakajima K (2000). [Worsened orthostatic hypotension due to levodopa administration in a case of Parkinson\u2019s disease]. Nihon Ronen Igakkai Zasshi, 37:255-258.","DOI":"10.3143\/geriatrics.37.255"},{"key":"key-10.14336\/AD.2021.0214-35","doi-asserted-by":"crossref","unstructured":"Mehagnoul-Schipper DJ, Boerman RH, Hoefnagels WH, Jansen RW (2001). Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients. J Gerontol A Biol Sci Med Sci, 56:M749-755.","DOI":"10.1093\/gerona\/56.12.M749"},{"key":"key-10.14336\/AD.2021.0214-36","doi-asserted-by":"crossref","unstructured":"Jost WH, Altmann C, Fiesel T, Becht B, Ringwald S, Hoppe T (2020). Influence of levodopa on orthostatic hypotension in Parkinson\u2019s Disease. Neurol Neurochir Pol, 54:200-203.","DOI":"10.5603\/PJNNS.a2020.0019"},{"key":"key-10.14336\/AD.2021.0214-37","doi-asserted-by":"crossref","unstructured":"Lang AE (2001). Acute orthostatic hypotension when starting dopamine agonist therapy in parkinson disease: the role of domperidone therapy. Arch Neurol, 58:835.","DOI":"10.1001\/archneur.58.5.835"},{"key":"key-10.14336\/AD.2021.0214-38","doi-asserted-by":"crossref","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG (2000). Acute orthostatic hypotension when starting dopamine agonists in Parkinson\u2019s disease. Arch Neurol, 57:1461-1463.","DOI":"10.1001\/archneur.57.10.1461"},{"key":"key-10.14336\/AD.2021.0214-39","doi-asserted-by":"crossref","unstructured":"Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. (2013). Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol, 12:747-755.","DOI":"10.1016\/S1474-4422(13)70117-0"},{"key":"key-10.14336\/AD.2021.0214-40","doi-asserted-by":"crossref","unstructured":"Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, et al. (1995). Pramipexole in patients with early Parkinson\u2019s disease. Clin Neuropharmacol, 18:338-347.","DOI":"10.1097\/00002826-199508000-00006"},{"key":"key-10.14336\/AD.2021.0214-41","unstructured":"Titlic M, Tonkic A, Jukic I, Lusic I, Dikanovic M (2008). Side effects of ropinirole in patients with idiopathic Parkinson\u2019s disease. Bratisl Lek Listy, 109:273-275."},{"key":"key-10.14336\/AD.2021.0214-42","unstructured":"Li SH, Chen HB, Wang ZF, Tang RH, Zhang XY, Yang JS, et al. (2013). [Efficacy and safety of ropinirole in the treatment of Parkinson\u2019s disease: a multi-center, randomized, double-blind and bromocriptine-controlled trial]. Zhonghua Yi Xue Za Zhi, 93:1952-1957."},{"key":"key-10.14336\/AD.2021.0214-43","doi-asserted-by":"crossref","unstructured":"Kim JM, Chung SJ, Kim JW, Jeon BS, Singh P, Thierfelder S, et al. (2015). Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson\u2019s disease: an open-label study. BMC Neurol, 15:17.","DOI":"10.1186\/s12883-015-0267-7"},{"key":"key-10.14336\/AD.2021.0214-44","doi-asserted-by":"crossref","unstructured":"Nicholas AP, Borgohain R, Chana P, Surmann E, Thompson EL, Bauer L, et al. (2014). A randomized study of rotigotine dose response on \u2019off\u2019 time in advanced Parkinson\u2019s disease. J Parkinsons Dis, 4:361-373.","DOI":"10.3233\/JPD-130320"},{"key":"key-10.14336\/AD.2021.0214-45","doi-asserted-by":"crossref","unstructured":"Sharabi Y, Goldstein DS (2011). Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci, 310:123-128.","DOI":"10.1016\/j.jns.2011.06.047"},{"key":"key-10.14336\/AD.2021.0214-46","doi-asserted-by":"crossref","unstructured":"Goldstein DS (2013). Sympathetic neuroimaging. Handb Clin Neurol, 117:365-370.","DOI":"10.1016\/B978-0-444-53491-0.00029-8"},{"key":"key-10.14336\/AD.2021.0214-47","doi-asserted-by":"crossref","unstructured":"Ruffoli R, Soldani P, Pasquali L, Ruggieri S, Paparelli A, Fornai F (2008). Methamphetamine fails to alter the noradrenergic integrity of the heart. Ann N Y Acad Sci, 1139:337-344.","DOI":"10.1196\/annals.1432.017"},{"key":"key-10.14336\/AD.2021.0214-48","doi-asserted-by":"crossref","unstructured":"Sharabi Y, Li ST, Dendi R, Holmes C, Goldstein DS (2003). Neurotransmitter specificity of sympathetic denervation in Parkinson\u2019s disease. Neurology, 60:1036-1039.","DOI":"10.1212\/01.WNL.0000052690.91036.FF"},{"key":"key-10.14336\/AD.2021.0214-49","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Imrich R, Peckham E, Holmes C, Lopez G, Crews C, et al. (2007). Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology, 69:1580-1584.","DOI":"10.1212\/01.wnl.0000268696.57912.64"},{"key":"key-10.14336\/AD.2021.0214-50","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A, et al. (2005). Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension, 46:1333-1339.","DOI":"10.1161\/01.HYP.0000188052.69549.e4"},{"key":"key-10.14336\/AD.2021.0214-51","doi-asserted-by":"crossref","unstructured":"Lucio CG, Vincenzo C, Antonio R, Oscar T, Antonio R, Luigi M (2013). Neurological applications for myocardial MIBG scintigraphy. Nucl Med Rev Cent East Eur, 16:35-41.","DOI":"10.5603\/NMR.2013.0007"},{"key":"key-10.14336\/AD.2021.0214-52","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Holmes C, Sewell L, Park MY, Sharabi Y (2012). Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. Clin Auton Res, 22:57-61.","DOI":"10.1007\/s10286-011-0136-4"},{"key":"key-10.14336\/AD.2021.0214-53","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak K, et al. (2009). Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Cleve Clin J Med, 76 Suppl 2:S47-50.","DOI":"10.3949\/ccjm.76.s2.10"},{"key":"key-10.14336\/AD.2021.0214-54","doi-asserted-by":"crossref","unstructured":"Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL (2001). Orthostatic hypotension in patients with Parkinson\u2019s disease: pathophysiology and management. Drugs Aging, 18:495-505.","DOI":"10.2165\/00002512-200118070-00003"},{"key":"key-10.14336\/AD.2021.0214-55","doi-asserted-by":"crossref","unstructured":"Lamotte G, Takahashi M, Wu T, Sullivan P, Cherup J, Holmes C, et al. (2021). Do indices of baroreflex failure and peripheral noradrenergic deficiency predict the magnitude of orthostatic hypotension in Lewy body diseases? Clin Auton Res.","DOI":"10.1007\/s10286-021-00788-4"},{"key":"key-10.14336\/AD.2021.0214-56","doi-asserted-by":"crossref","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. (2018). Hypertension. Nat Rev Dis Primers, 4:18014.","DOI":"10.1038\/nrdp.2018.14"},{"key":"key-10.14336\/AD.2021.0214-57","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y (2003). Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension, 42:136-142.","DOI":"10.1161\/01.HYP.0000081216.11623.C3"},{"key":"key-10.14336\/AD.2021.0214-58","doi-asserted-by":"crossref","unstructured":"Rahman F, Goldstein DS (2014). Quantitative indices of baroreflex-sympathoneural function: application to patients with chronic autonomic failure. Clin Auton Res, 24:103-110.","DOI":"10.1007\/s10286-014-0234-1"},{"key":"key-10.14336\/AD.2021.0214-59","doi-asserted-by":"crossref","unstructured":"Roy S, Jaryal AK, Srivastava AK, Deepak KK (2016). Cardiovagal Baroreflex Sensitivity in Parkinson\u2019s Disease and Multiple-System Atrophy. J Clin Neurol, 12:218-223.","DOI":"10.3988\/jcn.2016.12.2.2.218"},{"key":"key-10.14336\/AD.2021.0214-60","doi-asserted-by":"crossref","unstructured":"Cabral LM, Moreira TS, Takakura AC, Falquetto B (2020). Attenuated baroreflex in a Parkinson\u2019s disease animal model coincides with impaired activation of non-C1 neurons. Auton Neurosci, 225:102655.","DOI":"10.1016\/j.autneu.2020.102655"},{"key":"key-10.14336\/AD.2021.0214-61","doi-asserted-by":"crossref","unstructured":"Blaho A, Sutovsky S, Valkovic P, Siarnik P, Sykora M, Turcani P (2017). Decreased baroreflex sensitivity in Parkinson\u2019s disease is associated with orthostatic hypotension. J Neurol Sci, 377:207-211.","DOI":"10.1016\/j.jns.2017.03.044"},{"key":"key-10.14336\/AD.2021.0214-62","doi-asserted-by":"crossref","unstructured":"Jordan J, Shannon JR, Grogan E, Biaggioni I, Robertson D (1999). A potent pressor response elicited by drinking water. The Lancet, 353.","DOI":"10.1016\/S0140-6736(99)99015-3"},{"key":"key-10.14336\/AD.2021.0214-63","doi-asserted-by":"crossref","unstructured":"Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, et al. (2000). The pressor response to water drinking in humans : a sympathetic reflex? Circulation, 101:504-509.","DOI":"10.1161\/01.CIR.101.5.504"},{"key":"key-10.14336\/AD.2021.0214-64","doi-asserted-by":"crossref","unstructured":"Vianna LC, Fernandes IA, Martinez DG, Teixeira AL, Silva BM, Fadel PJ, et al. (2018). Water drinking enhances the gain of arterial baroreflex control of muscle sympathetic nerve activity in healthy young humans. Exp Physiol, 103:1318-1325.","DOI":"10.1113\/EP087095"},{"key":"key-10.14336\/AD.2021.0214-65","doi-asserted-by":"crossref","unstructured":"Jordan J (2005). Effect of water drinking on sympathetic nervous activity and blood pressure. Curr Hypertens Rep, 7:17-20.","DOI":"10.1007\/s11906-005-0050-z"},{"key":"key-10.14336\/AD.2021.0214-66","doi-asserted-by":"crossref","unstructured":"Ganesan M, Sathyaprabha TN, Gupta A, Pal PK (2014). Effect of partial weight-supported treadmill gait training on balance in patients with Parkinson disease. PM R, 6:22-33.","DOI":"10.1016\/j.pmrj.2013.08.604"},{"key":"key-10.14336\/AD.2021.0214-67","doi-asserted-by":"crossref","unstructured":"Rowell LB, Detry JM, Blackmon JR, Wyss C (1972). Importance of the splanchnic vascular bed in human blood pressure regulation. J Appl Physiol, 32:213-220.","DOI":"10.1152\/jappl.1972.32.2.213"},{"key":"key-10.14336\/AD.2021.0214-68","doi-asserted-by":"crossref","unstructured":"Podoleanu C, Maggi R, Brignole M, Croci F, Incze A, Solano A, et al. (2006). Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol, 48:1425-1432.","DOI":"10.1016\/j.jacc.2006.06.052"},{"key":"key-10.14336\/AD.2021.0214-69","doi-asserted-by":"crossref","unstructured":"Fanciulli A, Goebel G, Metzler B, Sprenger F, Poewe W, Wenning GK, et al. (2016). Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson\u2019s Disease. Mov Disord Clin Pract, 3:156-160.","DOI":"10.1002\/mdc3.12270"},{"key":"key-10.14336\/AD.2021.0214-70","doi-asserted-by":"crossref","unstructured":"Okamoto LE, Diedrich A, Baudenbacher FJ, Harder R, Whitfield JS, Iqbal F, et al. (2016). Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine. Hypertension, 68:418-426.","DOI":"10.1161\/HYPERTENSIONAHA.116.07199"},{"key":"key-10.14336\/AD.2021.0214-71","doi-asserted-by":"crossref","unstructured":"Bouvette CM, McPhee BR, Opfer-Gehrking TL, Low PA (1996). Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc, 71:847-853.","DOI":"10.4065\/71.9.847"},{"key":"key-10.14336\/AD.2021.0214-72","doi-asserted-by":"crossref","unstructured":"Gronek P, Wielinski D, Cyganski P, Rynkiewicz A, Zajac A, Maszczyk A, et al. (2020). A Review of Exercise as Medicine in Cardiovascular Disease: Pathology and Mechanism. Aging Dis, 11:327-340.","DOI":"10.14336\/AD.2019.0516"},{"key":"key-10.14336\/AD.2021.0214-73","doi-asserted-by":"crossref","unstructured":"Schroeder C, Bush VE, Norcliffe LJ, Luft FC, Tank J, Jordan J, et al. (2002). Water drinking acutely improves orthostatic tolerance in healthy subjects. Circulation, 106:2806-2811.","DOI":"10.1161\/01.CIR.0000038921.64575.D0"},{"key":"key-10.14336\/AD.2021.0214-74","doi-asserted-by":"crossref","unstructured":"Newton JL, Frith J (2018). The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. Neurology, 91:e652-e656.","DOI":"10.1212\/WNL.0000000000005994"},{"key":"key-10.14336\/AD.2021.0214-75","unstructured":"ten Harkel AD, Baisch F, Karemaker JM (1992). Increased orthostatic blood pressure variability after prolonged head-down tilt. Acta Physiol Scand Suppl, 604:89-99."},{"key":"key-10.14336\/AD.2021.0214-76","doi-asserted-by":"crossref","unstructured":"van Lieshout JJ, ten Harkel AD, Wieling W (2000). Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res, 10:35-42.","DOI":"10.1007\/BF02291388"},{"key":"key-10.14336\/AD.2021.0214-77","doi-asserted-by":"crossref","unstructured":"Bitner A, Zalewski P, Klawe JJ, Newton JL (2015). Drug Interactions in Parkinson\u2019s Disease: Safety of Pharmacotherapy for Arterial Hypertension. Drugs Real World Outcomes, 2:1-12.","DOI":"10.1007\/s40801-015-0008-7"},{"key":"key-10.14336\/AD.2021.0214-78","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Sharabi Y (2009). Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation, 119:139-146.","DOI":"10.1161\/CIRCULATIONAHA.108.805887"},{"key":"key-10.14336\/AD.2021.0214-79","doi-asserted-by":"crossref","unstructured":"Palma JA, Kaufmann H (2018). Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord, 33:372-390.","DOI":"10.1002\/mds.27344"},{"key":"key-10.14336\/AD.2021.0214-80","doi-asserted-by":"crossref","unstructured":"Shibao CA, Kaufmann H (2017). Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease. CNS Drugs, 31:975-989.","DOI":"10.1007\/s40263-017-0473-5"},{"key":"key-10.14336\/AD.2021.0214-81","doi-asserted-by":"crossref","unstructured":"Low PA, Singer W (2008). Management of neurogenic orthostatic hypotension: an update. Lancet Neurol, 7:451-458.","DOI":"10.1016\/S1474-4422(08)70088-7"},{"key":"key-10.14336\/AD.2021.0214-82","unstructured":"Schirger A, Sheps SG, Thomas JE, Fealey RD (1981). Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome. Mayo Clin Proc, 56:429-433."},{"key":"key-10.14336\/AD.2021.0214-83","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J (1988). Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology, 38:951-956.","DOI":"10.1212\/WNL.38.6.951"},{"key":"key-10.14336\/AD.2021.0214-84","doi-asserted-by":"crossref","unstructured":"Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA (1997). Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA, 277:1046-1051.","DOI":"10.1001\/jama.277.13.1046"},{"key":"key-10.14336\/AD.2021.0214-85","doi-asserted-by":"crossref","unstructured":"Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. (1998). A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology, 51:120-124.","DOI":"10.1212\/WNL.51.1.120"},{"key":"key-10.14336\/AD.2021.0214-86","doi-asserted-by":"crossref","unstructured":"Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA (2003). Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry, 74:1294-1298.","DOI":"10.1136\/jnnp.74.9.1294"},{"key":"key-10.14336\/AD.2021.0214-87","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Norcliffe-Kaufmann L, Palma JA (2015). Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther, 13:875-891.","DOI":"10.1586\/14779072.2015.1057504"},{"key":"key-10.14336\/AD.2021.0214-88","doi-asserted-by":"crossref","unstructured":"Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. (2017). The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol, 264:1567-1582.","DOI":"10.1007\/s00415-016-8375-x"},{"key":"key-10.14336\/AD.2021.0214-89","doi-asserted-by":"crossref","unstructured":"Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H (2017). Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol, 17:90.","DOI":"10.1186\/s12883-017-0867-5"},{"key":"key-10.14336\/AD.2021.0214-90","doi-asserted-by":"crossref","unstructured":"Hauser RA, Hewitt LA, Isaacson S (2014). Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson\u2019s disease (NOH306A). J Parkinsons Dis, 4:57-65.","DOI":"10.3233\/JPD-130259"},{"key":"key-10.14336\/AD.2021.0214-91","doi-asserted-by":"crossref","unstructured":"Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, et al. (2015). Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension, 65:101-107.","DOI":"10.1161\/HYPERTENSIONAHA.114.04035"},{"key":"key-10.14336\/AD.2021.0214-92","unstructured":"Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G (2015). Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson\u2019s disease (nOH306B). Mov Disord, 30:646-654."},{"key":"key-10.14336\/AD.2021.0214-93","doi-asserted-by":"crossref","unstructured":"Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH (2016). Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol, 39:220-226.","DOI":"10.1097\/WNF.0000000000000168"},{"key":"key-10.14336\/AD.2021.0214-94","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. (2014). Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology, 83:328-335.","DOI":"10.1212\/WNL.0000000000000615"},{"key":"key-10.14336\/AD.2021.0214-95","doi-asserted-by":"crossref","unstructured":"Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ (2016). Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303). J Parkinsons Dis, 6:751-759.","DOI":"10.3233\/JPD-160860"},{"key":"key-10.14336\/AD.2021.0214-96","doi-asserted-by":"crossref","unstructured":"Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB (2016). Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. J Am Soc Hypertens, 10:755-762.","DOI":"10.1016\/j.jash.2016.07.010"},{"key":"key-10.14336\/AD.2021.0214-97","doi-asserted-by":"crossref","unstructured":"Hauser RA, Biaggioni I, Hewitt LA, Vernino S (2018). Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Mov Disord Clin Pract, 5:627-634.","DOI":"10.1002\/mdc3.12695"},{"key":"key-10.14336\/AD.2021.0214-98","doi-asserted-by":"crossref","unstructured":"Lopes de Faria SR, Zanella MT, Andriolo A, Ribeiro AB, Chacra AR (1988). Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin Pharmacol Ther, 44:670-674.","DOI":"10.1038\/clpt.1988.210"},{"key":"key-10.14336\/AD.2021.0214-99","doi-asserted-by":"crossref","unstructured":"Montastruc JL, Chamontin B, Senard JM, Rascol A (1985). Domperidone in the management of orthostatic hypotension. Clin Neuropharmacol, 8:191-192.","DOI":"10.1097\/00002826-198506000-00010"},{"key":"key-10.14336\/AD.2021.0214-100","doi-asserted-by":"crossref","unstructured":"Capria A, Attanasio A, Quatrana M, Cannata D, Fioravanti M, Stocchi F, et al. (1989). Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson\u2019s disease. Clin Neuropharmacol, 12:331-338.","DOI":"10.1097\/00002826-198908000-00011"},{"key":"key-10.14336\/AD.2021.0214-101","doi-asserted-by":"crossref","unstructured":"Bacchi S, Chim I, Kramer P, Postuma RB (2017). Domperidone for Hypotension in Parkinson\u2019s Disease: A Systematic Review. J Parkinsons Dis, 7:603-617.","DOI":"10.3233\/JPD-171209"},{"key":"key-10.14336\/AD.2021.0214-102","doi-asserted-by":"crossref","unstructured":"Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, et al. (2003). Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord, 18:872-883.","DOI":"10.1002\/mds.10464"},{"key":"key-10.14336\/AD.2021.0214-103","doi-asserted-by":"crossref","unstructured":"Sandroni P, Opfer-Gehrking TL, Singer W, Low PA (2005). Pyridostigmine for treatment of neurogenic orthostatic hypotension [correction of hypertension]--a follow-up survey study. Clin Auton Res, 15:51-53.","DOI":"10.1007\/s10286-005-0225-3"},{"key":"key-10.14336\/AD.2021.0214-104","doi-asserted-by":"crossref","unstructured":"Schreglmann SR, Buchele F, Sommerauer M, Epprecht L, Kagi G, Hagele-Link S, et al. (2017). Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson\u2019s disease - a randomized controlled trial. Eur J Neurol, 24:545-551.","DOI":"10.1111\/ene.13260"},{"key":"key-10.14336\/AD.2021.0214-105","doi-asserted-by":"crossref","unstructured":"Byun JI, Kim DY, Moon J, Shin HR, Sunwoo JS, Lee WJ, et al. (2020). Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Ann Clin Transl Neurol, 7:112-120.","DOI":"10.1002\/acn3.50968"},{"key":"key-10.14336\/AD.2021.0214-106","doi-asserted-by":"crossref","unstructured":"ByunJI, KimDY, MoonJ, ShinHR, SunwooJS, LeeWJ, (2020). Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Ann Clin Transl Neurol, 7:402.","DOI":"10.1002\/acn3.51036"},{"key":"key-10.14336\/AD.2021.0214-107","doi-asserted-by":"crossref","unstructured":"Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, et al. (2019). Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. Hypertension, 73:235-241.","DOI":"10.1161\/HYPERTENSIONAHA.118.11790"},{"key":"key-10.14336\/AD.2021.0214-108","doi-asserted-by":"crossref","unstructured":"Patel H, Simpson A, Palevoda G, Hale GM (2018). Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults. J Clin Hypertens (Greenwich), 20:794-797.","DOI":"10.1111\/jch.13260"},{"key":"key-10.14336\/AD.2021.0214-109","doi-asserted-by":"crossref","unstructured":"Hale GM, Brenner M (2015). Atomoxetine for Orthostatic Hypotension in an Elderly Patient Over 10 Weeks: A Case Report. Pharmacotherapy, 35:e141-148.","DOI":"10.1002\/phar.1635"},{"key":"key-10.14336\/AD.2021.0214-110","doi-asserted-by":"crossref","unstructured":"Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, et al. (2014). Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension, 64:1235-1240.","DOI":"10.1161\/HYPERTENSIONAHA.114.04225"},{"key":"key-10.14336\/AD.2021.0214-111","doi-asserted-by":"crossref","unstructured":"Hoehn MM (1975). Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch Neurol, 32:50-51.","DOI":"10.1001\/archneur.1975.00490430072013"},{"key":"key-10.14336\/AD.2021.0214-112","unstructured":"Hakamaki T, Rajala T, Lehtonen A (1998). Ambulatory 24-hour blood pressure recordings in patients with Parkinson\u2019s disease with or without fludrocortisone. Int J Clin Pharmacol Ther, 36:367-369."},{"key":"key-10.14336\/AD.2021.0214-113","doi-asserted-by":"crossref","unstructured":"Imaizumi T, Takeshita A, Ashihara T, Nakamura M, Tsuji S, Shibazaki H (1984). Increase in reflex vasoconstriction with indomethacin in patients with orthostatic hypotension and central nervous system involvement. Br Heart J, 52:581-584.","DOI":"10.1136\/hrt.52.5.581"},{"key":"key-10.14336\/AD.2021.0214-114","unstructured":"Thilothammal N, Dhanaraj M, Kumaresan G, Jagannathan K (1986). Treatment of neurogenic orthostatic hypotension with indomethacin. J Assoc Physicians India, 34:276-277."},{"key":"key-10.14336\/AD.2021.0214-115","doi-asserted-by":"crossref","unstructured":"Biaggioni I, Robertson RM (2002). Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin, 20:291-301, vii.","DOI":"10.1016\/S0733-8651(01)00005-4"},{"key":"key-10.14336\/AD.2021.0214-116","doi-asserted-by":"crossref","unstructured":"Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H (2000). Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet, 355:725-726.","DOI":"10.1016\/S0140-6736(99)05320-9"},{"key":"key-10.14336\/AD.2021.0214-117","doi-asserted-by":"crossref","unstructured":"Garland EM, Gamboa A, Okamoto L, Raj SR, Black BK, Davis TL, et al. (2009). Renal impairment of pure autonomic failure. Hypertension, 54:1057-1061.","DOI":"10.1161\/HYPERTENSIONAHA.109.136853"},{"key":"key-10.14336\/AD.2021.0214-118","doi-asserted-by":"crossref","unstructured":"Tian J, Popal MS, Zhao Y, Liu Y, Chen K, Liu Y (2019). Interplay between Exosomes and Autophagy in Cardiovascular Diseases: Novel Promising Target for Diagnostic and Therapeutic Application. Aging Dis, 10:1302-1310.","DOI":"10.14336\/AD.2018.1020"},{"key":"key-10.14336\/AD.2021.0214-119","doi-asserted-by":"crossref","unstructured":"Palma JA, Redel-Traub G, Porciuncula A, Samaniego-Toro D, Millar Vernetti P, Lui YW, et al. (2020). The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension. Parkinsonism Relat Disord, 75:97-104.","DOI":"10.1016\/j.parkreldis.2020.04.011"},{"key":"key-10.14336\/AD.2021.0214-120","doi-asserted-by":"crossref","unstructured":"Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, et al. (2006). Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension, 47:522-526.","DOI":"10.1161\/01.HYP.0000199982.71858.11"},{"key":"key-10.14336\/AD.2021.0214-121","doi-asserted-by":"crossref","unstructured":"Okamoto LE, Celedonio JE, Gamboa A, Shibao CA, Raj SR, Diedrich A, et al. (2016). Blood Pressure-Lowering Effect of Local Passive Heat in Autonomic Failure Patients with Supine Hypertension. Hypertension, 68.","DOI":"10.1161\/hyp.68.suppl_1.022"},{"key":"key-10.14336\/AD.2021.0214-122","doi-asserted-by":"crossref","unstructured":"Tian J, Popal MS, Huang R, Zhang M, Zhao X, Zhang M, et al. (2020). Caveolin as a Novel Potential Therapeutic Target in Cardiac and Vascular Diseases: A Mini Review. Aging Dis, 11:378-389.","DOI":"10.14336\/AD.2019.09603"},{"key":"key-10.14336\/AD.2021.0214-123","doi-asserted-by":"crossref","unstructured":"Pathak A, Senard JM (2006). Blood pressure disorders during Parkinson\u2019s disease: epidemiology, pathophysiology and management. Expert Rev Neurother, 6:1173-1180.","DOI":"10.1586\/14737175.6.8.1173"},{"key":"key-10.14336\/AD.2021.0214-124","doi-asserted-by":"crossref","unstructured":"Jordan J, Shannon JR, Pohar B, Paranjape SY, Robertson D, Robertson RM, et al. (1999). Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol, 10:35-42.","DOI":"10.1681\/ASN.V10135"},{"key":"key-10.14336\/AD.2021.0214-125","doi-asserted-by":"crossref","unstructured":"de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Claassen J, Group NS (2019). Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension, 74:1172-1180.","DOI":"10.1161\/HYPERTENSIONAHA.119.13664"},{"key":"key-10.14336\/AD.2021.0214-126","doi-asserted-by":"crossref","unstructured":"Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, et al. (2019). Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet, 394:1011-1021.","DOI":"10.1016\/S0140-6736(19)31282-6"},{"key":"key-10.14336\/AD.2021.0214-127","doi-asserted-by":"crossref","unstructured":"Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ (1995). Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc, 43:1191-1197.","DOI":"10.1111\/j.1532-5415.1995.tb07393.x"},{"key":"key-10.14336\/AD.2021.0214-128","doi-asserted-by":"crossref","unstructured":"Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, et al. (2021). Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med, 9:85-95.","DOI":"10.1016\/S2213-2600(20)30356-8"},{"key":"key-10.14336\/AD.2021.0214-129","doi-asserted-by":"crossref","unstructured":"Pels A, Derks J, Elvan-Taspinar A, van Drongelen J, de Boer M, Duvekot H, et al. (2020). Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial. JAMA Netw Open, 3:e205323.","DOI":"10.1001\/jamanetworkopen.2020.5323"},{"key":"key-10.14336\/AD.2021.0214-130","doi-asserted-by":"crossref","unstructured":"Gamboa A, Shibao C, Diedrich A, Paranjape SY, Farley G, Christman B, et al. (2008). Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure. Hypertension, 51:1531-1536.","DOI":"10.1161\/HYPERTENSIONAHA.107.105171"},{"key":"key-10.14336\/AD.2021.0214-131","doi-asserted-by":"crossref","unstructured":"Okamoto LE, Gamboa A, Shibao CA, Arnold AC, Choi L, Black BK, et al. (2014). Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension. Hypertension, 64:1241-1247.","DOI":"10.1161\/HYPERTENSIONAHA.114.04116"},{"key":"key-10.14336\/AD.2021.0214-132","doi-asserted-by":"crossref","unstructured":"Arnold AC, Okamoto LE, Gamboa A, Black BK, Raj SR, Elijovich F, et al. (2016). Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure. Hypertension, 67:424-429.","DOI":"10.1161\/HYPERTENSIONAHA.115.06617"},{"key":"key-10.14336\/AD.2021.0214-133","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, Harris RA, Culliford L, Ellis L, et al. (2020). Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet, 395:294-303."},{"key":"key-10.14336\/AD.2021.0214-134","doi-asserted-by":"crossref","unstructured":"Lotery A, O\u2019Connell A, Harris RA, Sivaprasad S, Reeves BC (2020). Eplerenone for chronic central serous chorioretinopathy - Authors\u2019 reply. Lancet, 396:1557-1558.","DOI":"10.1016\/S0140-6736(20)32321-7"},{"key":"key-10.14336\/AD.2021.0214-135","doi-asserted-by":"crossref","unstructured":"Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, et al. (2013). Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension, 61:701-706.","DOI":"10.1161\/HYPERTENSIONAHA.111.00377"},{"key":"key-10.14336\/AD.2021.0214-136","doi-asserted-by":"crossref","unstructured":"Moriwaki H, Uno H, Nagakane Y, Hayashida K, Miyashita K, Naritomi H (2004). Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke. J Hum Hypertens, 18:693-699.","DOI":"10.1038\/sj.jhh.1001735"},{"key":"key-10.14336\/AD.2021.0214-137","doi-asserted-by":"crossref","unstructured":"Kario K, Ishikawa J, Hoshide S, Matsui Y, Morinari M, Eguchi K, et al. (2005). Diabetic brain damage in hypertension: role of renin-angiotensin system. Hypertension, 45:887-893.","DOI":"10.1161\/01.HYP.0000163460.07639.3f"},{"key":"key-10.14336\/AD.2021.0214-138","doi-asserted-by":"crossref","unstructured":"Onrot J, Goldberg MR, Biaggioni I, Hollister AS, Kingaid D, Robertson D (1985). Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med, 313:549-554.","DOI":"10.1056\/NEJM198508293130905"},{"key":"key-10.14336\/AD.2021.0214-139","doi-asserted-by":"crossref","unstructured":"Chaudhuri KR, Ellis C, Love-Jones S, Thomaides T, Clift S, Mathias CJ, et al. (1997). Postprandial hypotension and parkinsonian state in Parkinson\u2019s disease. Mov Disord, 12:877-884.","DOI":"10.1002\/mds.870120608"},{"key":"key-10.14336\/AD.2021.0214-140","doi-asserted-by":"crossref","unstructured":"Yalcin A, Atmis V, Cengiz OK, Cinar E, Aras S, Varli M, et al. (2016). Evaluation of Cardiac Autonomic Functions in Older Parkinson\u2019s Disease Patients: a Cross-Sectional Study. Aging Dis, 7:28-35.","DOI":"10.14336\/AD.2015.0819"},{"key":"key-10.14336\/AD.2021.0214-141","doi-asserted-by":"crossref","unstructured":"Puvi-Rajasingham S, Mathias CJ (1996). Effect of meal size on post-prandial blood pressure and on postural hypotension in primary autonomic failure. Clin Auton Res, 6:111-114.","DOI":"10.1007\/BF02291232"},{"key":"key-10.14336\/AD.2021.0214-142","doi-asserted-by":"crossref","unstructured":"Mathias CJ (1991). Postprandial hypotension. Pathophysiological mechanisms and clinical implications in different disorders. Hypertension, 18:694-704.","DOI":"10.1161\/01.HYP.18.5.694"},{"key":"key-10.14336\/AD.2021.0214-143","doi-asserted-by":"crossref","unstructured":"Visvanathan R, Chen R, Garcia M, Horowitz M, Chapman I (2005). The effects of drinks made from simple sugars on blood pressure in healthy older people. Br J Nutr, 93:575-579.","DOI":"10.1079\/BJN20051401"},{"key":"key-10.14336\/AD.2021.0214-144","doi-asserted-by":"crossref","unstructured":"Pfeiffer RF (2012). Autonomic dysfunction in Parkinson\u2019s disease. Expert Rev Neurother, 12:697-706.","DOI":"10.1586\/ern.12.17"},{"key":"key-10.14336\/AD.2021.0214-145","doi-asserted-by":"crossref","unstructured":"Ma K, Xiong N, Shen Y, Han C, Liu L, Zhang G, et al. (2018). Weight Loss and Malnutrition in Patients with Parkinson\u2019s Disease: Current Knowledge and Future Prospects. Front Aging Neurosci, 10:1.","DOI":"10.3389\/fnagi.2018.00001"},{"key":"key-10.14336\/AD.2021.0214-146","doi-asserted-by":"crossref","unstructured":"Lipsitz LA, Nyquist RP, Jr., Wei JY, Rowe JW (1983). Postprandial reduction in blood pressure in the elderly. N Engl J Med, 309:81-83.","DOI":"10.1056\/NEJM198307143090205"},{"key":"key-10.14336\/AD.2021.0214-147","doi-asserted-by":"crossref","unstructured":"Jansen RW, Penterman BJ, van Lier HJ, Hoefnagels WH (1987). Blood pressure reduction after oral glucose loading and its relation to age, blood pressure and insulin. Am J Cardiol, 60:1087-1091.","DOI":"10.1016\/0002-9149(87)90358-4"},{"key":"key-10.14336\/AD.2021.0214-148","doi-asserted-by":"crossref","unstructured":"Hoeldtke RD, O\u2019Dorisio TM, Boden G (1986). Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. Lancet, 2:602-605.","DOI":"10.1016\/S0140-6736(86)92428-1"},{"key":"key-10.14336\/AD.2021.0214-149","doi-asserted-by":"crossref","unstructured":"Jansen RW, Peeters TL, Lenders JW, van Lier HJ, v\u2019t Laar A, Hoefnagels WH (1989). Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly. J Clin Endocrinol Metab, 68:752-756.","DOI":"10.1210\/jcem-68-4-752"},{"key":"key-10.14336\/AD.2021.0214-150","doi-asserted-by":"crossref","unstructured":"Cho YS, Ko IG, Kim SE, Hwan L, Shin MS, Kim CJ, et al. (2014). Caffeine enhances micturition through neuronal activation in micturition centers. Mol Med Rep, 10:2931-2936.","DOI":"10.3892\/mmr.2014.2646"},{"key":"key-10.14336\/AD.2021.0214-151","doi-asserted-by":"crossref","unstructured":"Eschlbock S, Wenning G, Fanciulli A (2017). Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna), 124:1567-1605.","DOI":"10.1007\/s00702-017-1791-y"},{"key":"key-10.14336\/AD.2021.0214-152","doi-asserted-by":"crossref","unstructured":"Pathak A, Senard JM (2004). Pharmacology of orthostatic hypotension in Parkinson\u2019s disease: from pathophysiology to management. Expert Rev Cardiovasc Ther, 2:393-403.","DOI":"10.1586\/14779072.2.3.393"},{"key":"key-10.14336\/AD.2021.0214-153","doi-asserted-by":"crossref","unstructured":"Cicconetti P, Ciotti V, Monteforte G, Moise A, Chiarotti F, Piccirillo G, et al.(2003). Circadian blood pressure pattern and cognitive function in newly diagnosed older hypertensives. Blood Press, 12:168-174.","DOI":"10.1080\/08037050310011821"},{"key":"key-10.14336\/AD.2021.0214-154","doi-asserted-by":"crossref","unstructured":"Routledge F, McFetridge-Durdle J (2007). Nondipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs, 6:9-26.","DOI":"10.1016\/j.ejcnurse.2006.05.001"},{"key":"key-10.14336\/AD.2021.0214-155","doi-asserted-by":"crossref","unstructured":"Paganini-Hill A, Bryant N, Corrada MM, Greenia DE, Fletcher E, Singh B, et al. (2019). Blood Pressure Circadian Variation, Cognition and Brain Imaging in 90+ Year-Olds. Front Aging Neurosci, 11:54.","DOI":"10.3389\/fnagi.2019.00054"},{"key":"key-10.14336\/AD.2021.0214-156","doi-asserted-by":"crossref","unstructured":"Bellosta Diago E, Perez-Perez J, Santos Lasaosa S, Viloria Alebesque A, Martinez-Horta S, Kulisevsky J, et al. (2018). Neurocardiovascular pathology in pre-manifest and early-stage Huntington\u2019s disease. Eur J Neurol, 25:956-962.","DOI":"10.1111\/ene.13630"},{"key":"key-10.14336\/AD.2021.0214-157","unstructured":"Birkenhager AM, van den Meiracker AH (2007). Causes and consequences of a non-dipping blood pressure profile. Neth J Med, 65:127-131."},{"key":"key-10.14336\/AD.2021.0214-158","doi-asserted-by":"crossref","unstructured":"Milazzo V, Di Stefano C, Vallelonga F, Sobrero G, Zibetti M, Romagnolo A, et al. (2018). Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. Parkinsonism Relat Disord, 56:82-87.","DOI":"10.1016\/j.parkreldis.2018.06.032"},{"key":"key-10.14336\/AD.2021.0214-159","doi-asserted-by":"crossref","unstructured":"Mayer CC, Schmaderer C, Loutradis C, Matschkal J, Theodorakopoulou M, Lorenz G, et al. (2020). Heart Failure and Atrial Fibrillation Modify the Associations of Nocturnal Blood Pressure Dipping Pattern With Mortality in Hemodialysis Patients. Hypertension, 76:1231-1239.","DOI":"10.1161\/HYPERTENSIONAHA.120.15420"},{"key":"key-10.14336\/AD.2021.0214-160","doi-asserted-by":"crossref","unstructured":"Li K, Li J, Zheng J, Qin S (2019). Reactive Astrocytes in Neurodegenerative Diseases. Aging Dis, 10:664-675.","DOI":"10.14336\/AD.2018.0720"},{"key":"key-10.14336\/AD.2021.0214-161","doi-asserted-by":"crossref","unstructured":"Chung HY, Kim DH, Lee EK, Chung KW, Chung S, Lee B, et al. (2019). Redefining Chronic Inflammation in Aging and Age-Related Diseases: Proposal of the Senoinflammation Concept. Aging Dis, 10:367-382.","DOI":"10.14336\/AD.2018.0324"},{"key":"key-10.14336\/AD.2021.0214-162","doi-asserted-by":"crossref","unstructured":"Sarkar SN, Russell AE, Engler-Chiurazzi EB, Porter KN, Simpkins JW (2019). MicroRNAs and the Genetic Nexus of Brain Aging, Neuroinflammation, Neurodegeneration, and Brain Trauma. Aging Dis, 10:329-352.","DOI":"10.14336\/AD.2018.0409"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T18:28:09Z","timestamp":1633026489000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2021.0214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":162,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2021.0214","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}